Protagonist Therapeutics, Inc
PTGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001377121
In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $33.1M in total
- 2
- 13F holdersQ2 2026, +27 vs. previous quarter
- 346
- 13F valueReported value at the end of Q2 2026
- $9.30B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding PTGX, Q2 2026
1 superinvestor reports holding Protagonist Therapeutics, Inc on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.6%
Protagonist Therapeutics, Inc's share of the portfolio
- Shares
- 208,900
- Value
- $25.6M
Latest insider trades
Open-market purchases and sales by Protagonist Therapeutics, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)9:17 PM ET | Sep 8-10 | 2 days | Patel Dinesh V PH DPresident and CEO | SSale | −125.0K | $145.92 | −$18.2M | −19.3%523.0K after | 3 lots10b5-1 |
| Aug 12, 2026 (view filing)6:43 PM ET | Aug 10-11 | 2 days | Patel Dinesh V PH DPresident and CEO | SSale | −100.0K | $148.91 | −$14.9M | −16.0%523.5K after | 2 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Waddill William D.Director | SSale | −9.00K | $117.94 | −$1.06M | −53.5%7.83K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 10 | 1 day | Waddill William D.Director | SSale | −9.00K | $107.68 | −$969.1K | −53.5%7.83K after | 10b5-1 |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Waddill William D.Director | SSale | −9.00K | $99.64 | −$896.8K | −53.5%7.83K after | 10b5-1 |
| May 14, 2026 (view filing) | May 12 | 2 days | Patel Dinesh V PH DPresident and CEO | SSale | −75.0K | $100.12 | −$7.51M | −12.5%523.5K after | Amended10b5-1 |
| May 11, 2026 (view filing) | May 7-8 | 4 days | Giraudo BryanDirector | SSale | −41.1K | $100.12 | −$4.12M | −76.4%12.7K after | 2 lots |
| May 11, 2026 (view filing) | May 7-8 | 4 days | Giraudo BryanDirector | SSale | −18.0K | $100.05 | −$1.80M | −100.0%0 after | 2 lots |
| Apr 21, 2026 (view filing) | Apr 20 | 1 day | Ali AsifChief Financial Officer | SSale | −1.75K | $105.47 | −$184.6K | −2.9%59.0K after | |
| Mar 27, 2026 (view filing) | Mar 26 | 1 day | Molina Arturo MDChief Medical Officer | SSale | −15.0K | $104.79 | −$1.57M | −15.1%84.1K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Protagonist Therapeutics, Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,307,837 | $1.26B | 0.02% | +528,468+5.4% | Added |
| Farallon Capital Management, L.L.C. | 6,348,906 | $778.2M | 4.56% | 00.0% | Unchanged |
| RTW Investments, LP | 5,061,175 | $620.4M | 5.30% | +2,1220.0% | Added |
| Vanguard Portfolio Management LLC | 3,629,298 | $444.9M | 0.02% | +148,087+4.3% | Added |
| Wellington Management Group LLP | 3,416,781 | $418.8M | 0.07% | −182,863−5.1% | Reduced |
| UBS Group AG | 3,399,221 | $416.7M | 0.07% | −1,778,575−34.4% | Reduced |
| State Street Corp | 3,321,554 | $407.2M | 0.01% | +204,805+6.6% | Added |
| Vanguard Capital Management LLC | 2,853,394 | $349.8M | 0.01% | +47,498+1.7% | Added |
| Johnson & Johnson | 2,449,183 | $300.2M | 37.59% | 00.0% | Unchanged |
| Invesco Ltd. | 2,340,667 | $286.9M | 0.02% | +175,997+8.1% | Added |